New York, New York, USA, 05/11/2017 /SubmitPressRelease123/
TGV-inhalonix, a New York drug development company behind ground-breaking Mul-1867 which gives hope to treating life-threatening, antibiotic-resistant bacterial lung infections in patients suffering from cystic fibrosis, announced that Mul-1867 has shown tremendous potential against clinical isolates of fungi from patients with cystic fibrosis and other severe lung infections.
The findings were published in Europe’s leading discovery journal - International Journal of Antimicrobial Agents - and will be presented at the upcoming ASM - 2017 conference in June.
News Source: http://www.WiredPRNews.com
